Innovative Devices and Futuristic Therapies

Clinical investigators at today’s “Innovative Devices and Futuristic Therapies” session during the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation, presented 12-month follow-up data from the ATLANTA Trial. The results include zero percent thrombosis in patients discontinuing dual anti-platelet therapy... 

Tags: angioplasty, Atlanta, bypass, Cardiovascular Research Foundation, Catania, CeloNova BioSciences Inc., Corrado Tamburino, Ferrarotto Hospital, Georgia, health care systems, hypersensitivity, implanted medical devices, industrial applications, insurance programs, ischemic heart disease, Italy, medical devices, myocardial infarction, myocardial infarctions, Newnan, stent implantation, Thomas A. Gordy, thrombosis, Tomography, Ultrasound

Boston Scientific Inc. announced comprehensive data from the TAXUS ATLAS clinical program

Boston Scientific Corporation today announced comprehensive data from the TAXUS ATLAS clinical program, a series of global, prospective, multi-center, single-arm, historically controlled trials, which evaluate the TAXUS® Liberte® Paclitaxel-Eluting Stent System in a variety of lesions and patient groups. The TAXUS Liberte Stent received U.S. Food and Drug Administration approval on Friday. Results... 

Tags: Auckland, Boston Scientific Corporation, Cardiovascular Research Foundation, Center for Cardiac and Vascular Research, DC, Europe, federal law, John A. Ormiston, Mark A. Turco, Mercy Hospital, Michigan, myocardial infarction, New Zealand, patient groups, Securities and Exchange Commission, thrombosis, US Food and Drug Administration, Washington, Washington Adventist Hospital

Similarly Low Rates in Patients With Diabetes Compared to Non-Diabetics

Boston Scientific Corporation (NYSE: BSX – News) today announced results from an analysis of nearly 7,500 patients from its TAXUS ARRIVE 1 and 2 registries, which are designed to confirm the performance of the TAXUS® Express2(TM) Paclitaxel-Eluting Coronary Stent System in real-world practice. The two-year pooled ARRIVE data showed that the TAXUS Stent reduced clinical restenosis in patients... 

Tags: angioplasty, Boston Scientific Corporation, cardiac disease, cardiogenic shock, Cardiovascular Research Foundation, congestive heart failure, DC, diabetes, Donald S. Baim, John M. Lasala, myocardial infarction, renal disease, Securities and Exchange Commission, St. Louis, thrombosis, thrombus, Washington, Washington University School of Medicine

coronary artery bypass graft, ischemic heart disease, coronary stent system, futuristic nursing, nursing breakthroughs in philippines, st lukes hospital phils taguig, st lukes hospital taguig